Preeclampsia Diagnostics Market Size, Share & COVID-19 Impact Analysis, By Test Type (Blood Tests and Urine Analysis), By Product (Instruments and Consumables) End-user (Hospitals, Specialty Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2019-2027

The global preeclampsia diagnostics market size was valued at USD 1.06 billion in 2019 and is projected to reach USD 2.52 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period.

This report covers COVID-19 impact analysis on Preeclampsia Diagnostics Market

Request Sample

Preeclampsia, a rapidly progressive disorder is characterized by elevated blood pressure and excessive protein in the urine of pregnant women. It is one of the hypertensive disorders of pregnancy, which is responsible for the acceleration of the maternal & perinatal morbidity and mortality rate across the developed and emerging nations. If not diagnosed at an early stage, it could lead to preterm birth and other complications, such as seizure or eclampsia, failure of organs, and death. For instance, according to the Preeclampsia Foundation, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 infant deaths each year globally.

The rapid rise in the prevalence of preeclampsia worldwide and the need to protect life are likely to boost the demand for diagnostic tools in the forthcoming years. According to the Preeclampsia Foundation, over 10 billion women around the globe develop preeclampsia every year and around 2.5 billion preterm births are caused by preeclampsia annually. Many players are focusing on strategic collaborations & partnerships for the development of innovative blood tests to detect biomarkers indicating preeclampsia. It is augmented to fuel the toxemia diagnosis market growth during the coming years. The growing adoption of a sedentary lifestyle and the increasing economic burden of preeclampsia around the globe are likely to elevate the need for effective diagnostics for the detection of early onset of preeclampsia.

Baby Boom and Overlapping Symptoms of Preeclampsia and COVID-19 in Pregnant Women to Drive Growth

The coronavirus pandemic has resulted in an unprecedented demand on our healthcare system. The emergence of COVID-19 cases has created global worries related to the elderly, children, and pregnant women. A significant increase in the preeclampsia testing has been witnessed during these days attributable to the rising number of pregnancies during lockdown, delayed or cancelled abortion cases due to the unavailability of midwives or healthcare facilities, and high risks associated with the incidence of preeclampsia among pregnant women positive for COVID-19.

According to a survey by UNICEF, the lockdown will lead to 7 million unwanted pregnancies globally. Moreover, there is an increased diagnostic dilemma associated with the existing COVID-19 cases and preeclampsia due to the presence of proteinuria found in both conditions. Moreover, a positive government support in the form of amendments of guidelines to handle prenatal cases and management of preeclampsia and to ensure availability of the healthcare facilities despite load on them will drive the demand for preeclampsia screening in the year 2020.

LATEST TRENDS

Request a Free sample to learn more about this report.

Growing Preference for Blood Tests Owing to its Accuracy and Launch of Novel Immunoassays

Preeclampsia is a serious condition affecting pregnant woman. Blood tests are getting more popular than urine tests with advancements is the technology, increased availability of the test kits for detection of preeclampsia biomarkers, and growing affordability for high cost blood tests.

For instance, in June 2019, NHS England approved two blood test products named Elecsys sFlt-1 and PlGF immunoassays of F. Hoffmann-La Roche Ltd. under the ‘Innovation and Technology Payment’ program. Through this, NHS plans to implement the usage of the ground-breaking innovative products within hospitals in Europe and further enhance the accessibility of novel diagnostic tools for preeclampsia among the healthcare professionals for the detection of pregnancy-induced hypertension. Thus, growing preference for blood tests has been witnessed in this market.

DRIVING FACTORS

Growing Prevalence of Preeclampsia Expected to Propel Demand for Novel Tests

A rapid rise in the prevalence of preeclampsia across the globe is one of the major factors that is likely to boost the demand for diagnostic tools for the condition in the coming years. Preeclampsia is affecting the health of both mothers and neonates in the developed, as well as emerging nations. According to the World Health Organization (WHO), the incidence rate of preeclampsia is seven times higher in the developing countries, as compared to the developed countries. As per a report published by the BMC journal, the prevalence of preeclampsia in the developing countries ranges from 1.8% to 16.7% and affects around 10% of pregnant women in Africa, which is remarkably higher than the global average prevalence of around 2%.

The rising maternal & perinatal mortality and morbidity rate is projected to increase the demand for the early diagnosis of preeclampsia among pregnant women. According to the British Charity Action on Pre-eclampsia (APEC), annually, 1000 babies die from preeclampsia and around seven mothers die each year due to complications associated with preeclampsia in the U.K.

Increased New Product Launches to Drive Market Growth

The rising incidence of preeclampsia has led to an increasing medical treatment cost among women with the condition and their newborns. For instance, according to a research report published by the American Journal of Obstetrics and Gynecology (AJOG), the aggregated cost of maternal healthcare and neonates born to mothers with preeclampsia was about one-third of the total U.S. healthcare costs of women living with preeclampsia.

Combined with this, several key players engaged in preeclampsia testing are offering more effective diagnostics through strategic partnerships between them and with many other research organizations. For instance, in February 2019, Diabetomics, Inc. launched Lumella, the first rapid, point-of-care test for preeclampsia assessment in India. Lumella provides an accurate estimation of protein biomarker, Glycosylated Fibronectin (GlyFN) present in pregnant women with preeclampsia.

An increasing knowledge about the signs & symptoms associated with preeclampsia among pregnant mothers and the rising awareness about the effective screening tools for the condition among the healthcare providers are likely to boost the preeclampsia testing market growth at a rapid rate in the coming years.

RESTRAINING FACTORS

Lack of awareness about the preeclampsia disease and available diagnostic tools in developing regions

A single elevated increase in the blood pressure does not effectively diagnose the preeclampsia in pregnant women. Despite the growing prevalence of preeclampsia many pregnant women across the globe lacks the knowledge about the term preeclampsia and the complications associated with it. Moreover, women who develop preeclampsia are not aware of this life‐threatening condition until late in their pregnancy when symptoms such as high blood pressure have already manifested.

Thus, despite high prevalence of the disease, the limited awareness about the disease restricts the market growth.

SEGMENTATION

By Test Type Analysis

Ability to Effectively Detect Biomarkers Will Drive Growth of Blood Tests Segment

Based on the test type, the market segments include blood tests and urine analysis. Among them, the blood tests segment held the largest preeclampsia diagnostics market share in the year 2019. It is projected to expand at a considerably high CAGR during the forecast period. This is attributable to the advantages offered by blood tests in effectively detecting the biomarkers that are responsible for preeclampsia. Many organizations are adopting the usage of blood tests for the detection of preeclampsia, which can further fuel the demand for more blood screening tests for the same in the near future.

Urine analysis through reagent strips is a highly preferred method of preliminary analysis of preeclampsia in the market. These urine tests are simple to use and are non-invasive point-of-care paper tests that are used for the measurement of misfolded proteins in the urine of pregnant mothers. For instance, February 2015, researchers at Ohio State and Nationwide Children’s Hospital have developed the Congo Red Dot (CRD) diagnostic test. Such innovations in urine tests are likely to accelerate the growth of this segment in the preeclampsia testing market in the forthcoming years.

By Product Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Growing Number of Product Launches to Drive Growth of Consumables Segment

Based on product type, the preeclampsia screening market segments include instruments and consumables. Among them, the consumables segment held the largest market share in the year 2019. An increasing launch of many reagents & kits by various players for the rapid detection of biomarkers indicating preeclampsia is expected to boost the demand for consumables in the upcoming years.

For instance, in July 2017, PerkinElmer Inc. developed DELFIA Xpress PlGF 1-2-3 assay, which is used during the first trimester. It can detect the levels of placental growth factor – a biomarker that is associated with preeclampsia in serum samples.

The instrument segment is projected to expand at a considerably high CAGR during the forecast period. The instruments are highly sensitive and also offer fast screening test for the biochemical markers for preeclampsia screening.

By End-user Analysis

Diagnostic Centers to Continue Its Dominance Backed by Presence of Unique Instruments

Based on end-user, the market is categorized into hospitals, specialty clinics, diagnostic centers, and others. Among them, the diagnostic centers segment captured major preeclampsia diagnostics market revenue. This is mainly because of the presence of advanced diagnostic instruments at these centers. They provide accurate detection of preeclampsia at the earlier stage.

The hospitals segment is anticipated to hold the second-largest share of the preeclampsia screening industry throughout the forecast period. This is attributed to the rising number of hospitals in the developing regions with improved healthcare infrastructures. Preeclampsia, if not diagnosed earlier, can increase the risk of preterm complications, further rising the rate of hospitalization delivery. Thus, increasing rates of hospitalization can boost the growth of this segment during the forecast period.

For instance, according to a research conducted by the Agency for Healthcare Research and Quality (AHRQ) in 2017, an estimated 176,925 cases of deliveries performed at hospitalization settings had preeclampsia and nearly one-third of the deliveries with preeclampsia had severe type of preeclampsia in the United States.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

Geographically, the market is fragmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among them, the North America market size stood at USD 401.9 million in 2019. The high adoption of technologically advanced products, rising awareness among the healthcare providers and patients about the severity of the disease, and significant healthcare spending would contribute to the growth of the market for Preeclampsia Diagnostics in this region.

Asia Pacific is the second-largest market after North America owing to the presence of ever-increasing population, high pregnancy rate, and the growing usage of fertility treatments further leading to the increasing number of pregnant women and the growing awareness about the disease. Moreover, the growing strategic partnerships among the leading players and diagnostic labs to establish their footprints and the increasing adoption of technologically advanced products in the region are likely to drive the market growth in this region.

Latin America and the Middle East & Africa hold massive potential for the growth owing to the rapidly increasing incidence of preeclampsia, rising disposable incomes, and gradually improving healthcare infrastructure.

KEY INDUSTRY PLAYERS

Strong Product Offerings by Key Players to Propel Preeclampsia Diagnostics Industry Growth

F. Hoffmann-La Roche Ltd., PerkinElmer Inc., and DRG INSTRUMENTS GMBH are the leading players in the market with a strong brand presence, combined with a wide range of product offerings. These players are likely to continue their dominance in the preeclampsia diagnostics area and generate significant revenue in the forthcoming years. It is because of their persistent investments in the research and development activities for the launch of cost-effective and highly advanced diagnostic kits to rapidly detect preeclampsia. Moreover, a strong focus on the strategic collaborations with other players & various research organizations for the development of effective tests for preeclampsia is likely to support the expansion of their footprints in the preeclampsia diagnostics market.

Other players engaged in the manufacturing and distribution of the preeclampsia diagnostics kits in the market include Thermo Fisher Scientific Inc., Diabetomics, Inc., Metabolomic Diagnostics Ltd., Sera Prognostics, Siemens Healthineers AG, and Bayer AG among others.

 LIST OF KEY COMPANIES PROFILED:

• F. Hoffmann-La Roche Ltd (Basel, Switzerland)


• PerkinElmer Inc. (Massachusetts, United States)


• DRG INSTRUMENTS GMBH (HE, Germany)


• Thermo Fisher Scientific Inc. (Massachusetts, United States)


• Diabetomics, Inc. (Massachusetts, United States)


• Metabolomic Diagnostics Ltd. (Munster, Ireland)


• Sera Prognostics (UT, United States)


• Siemens Healthineers AG (Erlangen, Germany)


• Bayer AG (Leverkusen, Germany)


• Others

KEY INDUSTRY DEVELOPMENTS:

• February 2019: Diabetomics announced the launch of Lumella, a rapid point-of-care test for Preeclampsia in Hydrabad.


• February 2016: Diabetomics, Inc. announced its strategic partnership with BD to conduct a newly developed pregnancy-specific metabolic assay for the early detection of preeclampsia and gestational diabetes.

REPORT COVERAGE

An Infographic Representation of Preeclampsia Diagnostics Market

View Full Infographic

To get information on various segments, share your queries with us

The preeclampsia diagnostics market research report provides detailed information regarding various insights of the market. Some of them are growth drivers, restraints, competitive landscape, regional analysis, and challenges. It further offers an analytical depiction of this market trends for Preeclampsia Diagnostics and estimations to illustrate the forthcoming investment pockets. The market is quantitatively analyzed from 2016 to 2027 to provide the financial competency of the market. The information gathered in the report has been taken from several primary and secondary sources.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation